The gene therapy industry is developing rapidly, and the market size may exceed US$30 billion in 2025

In recent years, as one of the potential tracks in the field of biomedicine, cell gene therapy has always attracted the attention of the industry
.
Affected by this, gene therapy clinical trials of CAR-T products, oncolytic virus products, and AAV products at home and abroad have also continued to increase
.
And with the industry's growing focus on gene therapy, the market continues to expand
.
According to data, since 2015, the global gene therapy industry has developed rapidly
.
From 2016 to 2020, the market size has grown from $50.
4 million to $2.
08 billion; the global gene therapy market is expected to reach $30.
54 billion by 2025
.
Based on the huge market prospects, China has begun to accelerate the development of the gene therapy market and issued a series of favorable policies
.
For example, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" proposes to focus on the development of immune cell therapy, stem cell therapy, gene therapy products and specific immunoglobulins
.
Focus on the development of industrialized preparation technologies for new biological drugs such as bifunctional antibodies, antibody conjugated drugs, polypeptide conjugated drugs, new recombinant protein vaccines, nucleic acid vaccines, cell therapy and gene therapy drugs
.
At the same time, it encourages and supports the cooperation between vaccine enterprises and enterprises of important raw and auxiliary materials, consumables, production equipment and packaging materials to improve the quality and technical level of various products
.
The industry believes that with the support of favorable policies, coupled with technological upgrading and capital increase, the cell gene therapy industry will become an emerging development direction in the medical field.
It is expected to maintain rapid growth in the next 20 years and profoundly change the way of human disease treatment
.
At present, out of optimism about the market, a large number of local pharmaceutical companies, including Fosun Kite, WuXi Junuo, and Legend Bio, have entered the market
.
It is understood that due to the high threshold and strict regulatory requirements in this industry, many companies in the industry chain have also ushered in more opportunities
.
Among them, it is worth mentioning that CDMO (that is, custom R&D and production organization) plays a crucial role in it
.
As a result, the market size of cell gene therapy CDMO has also begun to grow rapidly
.
According to data, the global market has grown from US$770 million in 2016 to US$1.
72 billion in 2020, with a compound annual growth rate of 22.
4%, and is expected to increase to US$7.
86 billion by 2025
.
However, it should be noted that although the size of the gene therapy market is gradually increasing, with the increasing number of entrants, some leading CDMO companies have also begun to deploy in the field of gene therapy, including Pharmaron Chemical and Proton Bio, etc.
field layout
.
In addition, many pharmaceutical equipment companies have also revealed plans to deploy cell gene therapy
.
For example, Tofflon recently disclosed the plan to issue A shares to specific objects in 2022, showing that the number of non-public issuance of shares to no more than 35 specific investors does not exceed 188,501,112 shares (no more than 30% of the company's total share capital before this issuance).
), plans to raise not more than 3.
2 billion yuan, mainly for the enrichment of the front-end product line (DS) of biopharmaceuticals and cell gene therapy, and the innovation and upgrading and expansion of the injection production line (DP)
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.